Table 1.
Control | LPS | Hypoxia | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Control | LPS | LPS+PSC | LPS+MK | LPS+PBN | H | H + PSC | H + MK | H + PBN | ||||||||||
% | MFI | % | MFI | % | MFI | % | MFI | % | MFI | % | MFI | % | MFI | % | MFI | % | MFI | |
Presentation molecules | ||||||||||||||||||
MHC II | 96·5 | 549·9 | 98·6 | 2260·9a | 96·9 | 1106·6b | 94·2 | 700·7b | 91·8 | 484·2b | 99·2b | 1085·2 | 93·1 | 660·7 | 75·9 | 160·9 | 82 | 367·9 |
Co-stimulatory/signalling molecules | ||||||||||||||||||
CD40 | 64·8 | 35·8 | 90·9a | 95·1a | 80·2 | 47·2b | 73·8b | 43·1b | 59·8b | 36·2b | 91·3a | 78·2a | 67·9c | 36·6c | 48·5c | 25·4c | 40·3c | 23·5c |
CD80 | 5·6 | 10·5 | 69·2a | 48·8a | 24·2 | 19b | 36·3b | 25·4b | 23·7b | 19·4b | 28a·b | 22·1a·b | 3 | 8·7c | 3·2 | 10·1 | 35·3 | 10·5 |
CD86 | 90·7 | 317·7 | 97·5 | 855·6a | 97 | 592·8 | 90·5 | 326·2b | 86·7 | 404·3b | 96·3 | 389·3b | 88·4 | 391·1 | 71·5 | 143·5 | 81·5 | 321·7 |
CD54 | 98·8 | 780·2 | 99·3 | 5343a | 98·5 | 2629·5b | 98·1 | 1416·6b | 97·7 | 1197b | 96·8 | 2504·4a·b | 96·2 | 867·4c | 97·7 | 673c | 99·3 | 1197c |
Maturation antigen | ||||||||||||||||||
CD83 | 12·4 | 16·4 | 49·7a | 47·3a | 17·4b | 18·8b | 16·6b | 19·1b | 34·9b | 26·5b | 54·1a | 43·8a | 5·2c | 12·1c | 5·4c | 13·3c | 18c | 19·1c |
Versus C P < 0·05,
versus lipopolysaccharide (LPS) P < 0·05,
versus H P < 0·05. Hypoxia and LPS conditions cause phenotypic and morphological changes in immature dendritic cells (iDCs). Stimulated DCs were analysed by flow cytometry for CD40, CD80, CD83, CD86, CD54 and human leucocyte antigen D-related (HLA-DR) surface marker expression. Mean fluorescence intensity (MFI) for hypoxia-DC and LPS-DC was higher than for non-stimulated cells, although conventional markers showed lower MFI intensity under hypoxia compared to LPS. MFI and expression of each marker are presented as mean ± standard deviation of six experiments. MHC: major histocompatibility complex; PSC: P-glycoprotein inhibition using valspodar; PBN: probenecid; MK: CAS 115104-28-4.